BioMarin Pharmaceutical Inc.

The hemophilia market is a challenging and competitive field but Sanofi is confident that fitusiran, which has just been given the green light by the US Food and Drug Administration (28 March), has th

Xiamen Amoytop Biotech, a Chinese biopharma focused on liver diseases and oncology, has stood out among its peers by becoming the first in years to acquire a pre-revenue compatriot biotech company. Sh

Less than two months after Pfizer opted to give up its rights to late-stage Sangamo Therapeutics-partnered hemophilia A gene therapy candidate giroctocogene fitelparvovec, the big pharma has decided t

BioMarin Pharmaceuticals foresees its achondroplasia drug Voxzogo (vosoritide) having a strong competitive position in the years to come given the drug’s established position and the “stickiness” of t